Furthermore, a humanized TGFβ-neutralizing antibody (Fresolimumab) and novel inhibitors of galectin-3, LPA1, LOXL2, PDGF, and AKT are being tested in clinical trials for potential IPF treatment. The gene discussed is AKT1; the disease is idiopathic pulmonary fibrosis.